Biosimilars Competition Act Letter
To: The Honorable
Dear Congressman Sarbanes and
We are writing to express our support for the Biosimilars Competition Act of 2018 (H.R. 6478). The undersigned stakeholders share your commitment to promoting a biosimilars market that will help reduce prescription drug costs for patients, payers, and taxpayers. We commend you for introducing this important legislation and look forward to working with you to enact it into law.
Spending on biologic drugs in
Regulators have long paid attention to settlements between brand and generic drugmakers that end patent dispute litigation to determine whether they are hindering the introduction of generics onto the market, denying patient access to lower-cost treatments. A 2003 law requires those settlements to be submitted to the
Two recent patent litigation settlements on Humira, the best-selling biologic in
We applaud your commitment to increasing patient access to lower cost, life-saving biosimilars, and we look forward to working with you to enact this important legislation into law.
Sincerely,
CVS Health Express Scripts Families
National Association of Chain Drug Stores (NACDS) Pharmaceutical Care Management Association (PCMA)
Prime Therapeutics
Public Citizen
Public Sector HealthCare Roundtable
Teachers' Retirement System of
Treasury Secretary Mnuchin Issues Statement on Medicare Board of Trustees Meeting
Pittsford Psychiatrist Charged With Health Care Fraud
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News